CC 92480

Drug Profile

CC 92480

Alternative Names: CC-92480

Latest Information Update: 27 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Celgene Corporation
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Ubiquitin protein ligase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Multiple myeloma

Most Recent Events

  • 27 Feb 2018 Celgene plans a phase I trial of CC 92480 for Multiple myeloma (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA in December 2017 (NCT03374085) (EudraCT2017-001236-19)
  • 06 Feb 2018 Phase-I clinical trials in Multiple myeloma (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (Celgene pipeline, February 2018) (NCT03374085)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top